Raju Prasad
Stock Analyst at William Blair
(0.02)
# 3,364
Out of 4,433 analysts
11
Total ratings
16.67%
Success rate
-47.19%
Average return
Main Sectors:
Top Industries:
9 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DTIL Precision BioSciences | Downgrades: Market Perform | n/a | $11.98 | - | 1 | Jun 9, 2022 | |
| NTLA Intellia Therapeutics | Initiates: Outperform | n/a | $26.17 | - | 1 | Feb 18, 2022 | |
| ASMB Assembly Biosciences | Downgrades: Market Perform | n/a | $14.72 | - | 1 | Sep 2, 2021 | |
| VERV Verve Therapeutics | Initiates: Outperform | n/a | $6.38 | - | 1 | Jul 12, 2021 | |
| TSHA Taysha Gene Therapies | Initiates: Outperform | n/a | $3.14 | - | 1 | Feb 24, 2021 | |
| GBIO Generation Bio Co. | Initiates: Outperform | n/a | $3.77 | - | 1 | Feb 24, 2021 | |
| CRSP CRISPR Therapeutics AG | Initiates: Market Perform | n/a | $55.67 | - | 1 | Mar 14, 2019 | |
| BOLD Boundless Bio | Downgrades: Market Perform | n/a | $9.96 | - | 2 | Nov 7, 2018 | |
| PTCT PTC Therapeutics | Upgrades: Outperform | n/a | $34.03 | - | 2 | Jun 18, 2018 |
Precision BioSciences
Jun 9, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $11.98
Upside: -
Intellia Therapeutics
Feb 18, 2022
Initiates: Outperform
Price Target: n/a
Current: $26.17
Upside: -
Assembly Biosciences
Sep 2, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $14.72
Upside: -
Verve Therapeutics
Jul 12, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.38
Upside: -
Taysha Gene Therapies
Feb 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.14
Upside: -
Generation Bio Co.
Feb 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.77
Upside: -
CRISPR Therapeutics AG
Mar 14, 2019
Initiates: Market Perform
Price Target: n/a
Current: $55.67
Upside: -
Boundless Bio
Nov 7, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $9.96
Upside: -
PTC Therapeutics
Jun 18, 2018
Upgrades: Outperform
Price Target: n/a
Current: $34.03
Upside: -